Baxter International Inc. (NYSE:BAX) Shares Sold by Transcend Capital Advisors LLC

Transcend Capital Advisors LLC reduced its position in Baxter International Inc. (NYSE:BAX) by 4.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,131 shares of the medical instruments supplier’s stock after selling 383 shares during the period. Transcend Capital Advisors LLC’s holdings in Baxter International were worth $266,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. CKW Financial Group lifted its stake in shares of Baxter International by 19.3% in the 4th quarter. CKW Financial Group now owns 2,625 shares of the medical instruments supplier’s stock valued at $77,000 after purchasing an additional 425 shares during the period. Farther Finance Advisors LLC raised its position in Baxter International by 23.2% during the third quarter. Farther Finance Advisors LLC now owns 2,519 shares of the medical instruments supplier’s stock worth $96,000 after acquiring an additional 475 shares during the period. LRI Investments LLC raised its position in Baxter International by 60.8% during the third quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier’s stock worth $59,000 after acquiring an additional 590 shares during the period. Fortitude Family Office LLC acquired a new position in Baxter International during the third quarter worth $38,000. Finally, Covestor Ltd raised its position in Baxter International by 23.4% during the third quarter. Covestor Ltd now owns 6,431 shares of the medical instruments supplier’s stock worth $244,000 after acquiring an additional 1,219 shares during the period. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Baxter International Price Performance

Baxter International stock opened at $33.87 on Monday. Baxter International Inc. has a 52-week low of $28.33 and a 52-week high of $44.01. The firm has a market capitalization of $17.29 billion, a price-to-earnings ratio of -26.46, a PEG ratio of 10.62 and a beta of 0.61. The company has a fifty day simple moving average of $30.65 and a 200-day simple moving average of $34.10. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31.

Baxter International (NYSE:BAX) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.52 by $0.06. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. The firm had revenue of $2.75 billion during the quarter, compared to analyst estimates of $2.67 billion. On average, equities analysts anticipate that Baxter International Inc. will post 2.48 EPS for the current fiscal year.

Baxter International Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be issued a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.01%. The ex-dividend date of this dividend is Friday, February 28th. Baxter International’s dividend payout ratio is currently -53.13%.

Analyst Ratings Changes

BAX has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reduced their price objective on shares of Baxter International from $38.00 to $36.00 and set a “neutral” rating for the company in a research report on Friday. Citigroup reduced their price objective on shares of Baxter International from $37.00 to $35.00 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. Stifel Nicolaus reduced their price objective on shares of Baxter International from $46.00 to $38.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Barclays initiated coverage on shares of Baxter International in a research report on Thursday. They set an “overweight” rating and a $39.00 price objective for the company. Finally, StockNews.com cut shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $38.80.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.